Protein Alternatives
A biotechnological company focused on the development and commercialization of biomarker-based assays for cancer diagnosis and therapeutic antibodies for treatment of metastatic tumors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €1.2m | Grant | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (38 %) | 2 % | 363 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 429 % | 384 % | 229 % | 98 % |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 34 % | (90 %) | (167 %) | (14 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Protein Alternatives (ProAlt) is a Spanish biotechnology company established in 2006 as a spin-off from the Spanish Research Council (CSIC) and the National Cancer Research Center (CNIO). The company focuses on two main areas within the oncology sector: developing therapeutic monoclonal antibodies for treating metastatic cancers and creating biomarker-based assays for early cancer diagnosis.
The company was founded by researchers from these prominent institutions, with Dr. Ignacio Casal leading the initial discoveries. Juan Ignacio Imbaud, who holds a Ph.D. in Molecular Biology, has been the CEO since its inception, guiding its business units which include Therapeutics, Diagnostics, and Contract Research/Manufacturing (CRO/CMO) services. ProAlt provides its expertise in protein and antibody design and production to third parties on a contractual basis.
ProAlt's main therapeutic candidate is the monoclonal antibody hPA-0661, designed for the treatment of metastatic colorectal cancer. The mechanism of action involves inhibiting the interaction between CDH17 and the α2β1 integrin, which plays a critical role in cancer metastasis. This blockade has been shown in studies to inhibit cell adhesion, migration, and proliferation, and significantly improved survival rates in preclinical models. Beyond colorectal cancer, the company's research extends to developing antibodies for metastatic tumors in breast and melanoma.
In addition to its therapeutic pipeline, ProAlt develops products for the early detection of colorectal cancer through blood-based tests and maintains a catalog of recombinant proteins and antibodies for research purposes. The company is headquartered in Tres Cantos, Madrid.
Keywords: monoclonal antibodies, cancer diagnostics, biomarker development, metastatic cancer, therapeutic antibodies, oncology, CRO services, CMO services, colorectal cancer, protein design